There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. After-hours trades for Adamis Pharmaceuticals Corporation (ADMP) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.0055, or -2.93%, to $0.182. The Adamis Pharmaceuticals Corporation has recorded 7,016 volume in the after hours trading session. Earlier, Yahoo Finance discussed this stock as it revealed Adamis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update.
This NASDAQ-listed company operates within the Drug Manufacturers – Specialty & Generic industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $0.19 and fluctuated between $0.2001 as its day high and $0.1850 as its day low. The current market capitalization of Adamis Pharmaceuticals Corporation is $27.95M. A total of 0.5 million shares were traded on the day, compared to an average of 793.19K shares.
Insider trades can also provide insight into a stock’s future direction. During the recent three months, ADMP has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 1 BUYs and 4 SELLs from insiders. Insiders purchased 250,000 shares during that period but sold 34,151.
In the most recent transaction, Moss Ronald B. sold 8,199 shares of ADMP for 0.60 per share on Mar 18. After the transaction, the Chief Medical Officer now owns 201,911 company shares. In a previous transaction on Mar 18, Marguglio David J. sold 11,859 shares at 0.60 per share. ADMP shares that SVP and Chief Business Officer owns now total 233,906.
Among the insiders who sold shares, CARLO DENNIS J PHD disposed of 10,490 shares on Mar 18 at a per-share price of $0.60. This resulted in the President & CEO holding 285,867 shares of ADMP after the transaction. In another insider transaction, Benedicto David C. sold 3,603 shares at $0.61 per share on Mar 18. Company shares held by the Chief Financial Officer now total 39,875.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for ADMP in the last 3 months, the mean price target is $1.50 with high estimates of $1.50 and low estimates of $1.50. In terms of 52-week highs and lows, ADMP has a high of $0.73 and a low of $0.12.
As of this writing, ADMP has an earnings estimate of -$0.03 per share for the current quarter. EPS was calculated based on a consensus of 1 estimates, with a high estimate of -$0.03 per share and a lower estimate of -$0.03. The company reported an EPS of -$0.07 in the last quarter, which was -133.30% lower than expectations of -$0.03.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects.
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 1 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ADMP is Buy with a score of 0.00. A total of 0 analysts rated the stock as Buy while 0 rated it as Overweight while 1 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.